Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458390 | 1.00 | ENPP2 (0.50) | ENPP2ORAI1ORAI2ORAI3SCN4A | |
| Methyl Alcohol SCHEMBL28303521 | 0.80 | ALDH1A1 (0.46) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL29401885 | 0.80 | ENPP2 (0.65) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL22690326 | 0.80 | CA1 (0.55) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL263451 | 0.80 | ENPP2 (0.65) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL145464 | 0.80 | ALDH1A1 (0.48) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL5198 | 0.78 | ENPP2 (0.47) | ENPP2ORAI1ORAI2ORAI3SLC6A4 | |
| SCHEMBL20983161 | 0.78 | ENPP2 (0.47) | ENPP2ORAI1ORAI2ORAI3TSHR | |
| SCHEMBL3787782 | 0.78 | ENPP2 (0.47) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL6651220 | 0.78 | ENPP2 (0.47) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12606573-B2 | Process for boron-containing compounds | VenatoRx Pharmaceuticals, Inc. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250255848-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-14 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-111148744-B | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119013251-A | Substituted 6, 7-dihydro-5H-benzo [7] rotaene derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2024-11-22 | — | — | CN | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-8629430-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110053939-A1 | NOVEL AROMATIC NITRO COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-03-03 | — | — | US | disclosed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1856058-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006094187-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | ENPP2 503/4885ORAI1 4048/4885ORAI2 3979/4885 |
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | ENPP2 2518/4885ORAI1 4502/4885ORAI2 4343/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ENPP2 2407/4885ORAI1 1960/4885ORAI2 4116/4885 |
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SOX18, ANXA1, ANXA11 | ENPP2 1316/4885ORAI1 1836/4885ORAI2 304/4885 |
| US-20250255848-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, FSHR, GPER1 | ENPP2 1725/4885ORAI1 661/4885ORAI2 2079/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ENPP2 2349/4885ORAI1 4439/4885ORAI2 4367/4885 |
| US-12606573-B2 | Process for boron-containing compounds | CYP1B1, LPO, BBOX1 | ENPP2 4658/4885ORAI1 2338/4885ORAI2 4187/4885 |
| US-20110053939-A1 | NOVEL AROMATIC NITRO COMPOUNDS | SELP, SELE, SELL | ENPP2 1424/4885ORAI1 3152/4885ORAI2 4326/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | ENPP2 557/4885ORAI1 3022/4885ORAI2 2486/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | ENPP2 1509/4885ORAI1 2701/4885ORAI2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.